Julia Owens: A Deep Dive Into Stroke Care and Basking Bio’s Innovative Programs
Julia Owens, Chief Executive Officer at Basking Biosciences Inc, reposted from Basking Biosciences, Inc. on LinkedIn:
”I have long admired Josh Schimmer‘s biotech insights and wit, so I was thrilled when he wanted to learn more about our work at Basking Bio.
I hope you will listen to this webinar where Josh and Alexa dig into the background of stroke care and our innovative programs with their usual probing questions.”
Quoting Basking Biosciences, Inc.‘s post:
”We had the privilege of joining Josh Schimmer and Alexa Deemer Conzola at Cantor Fitzgerald for a deep dive into acute ischemic stroke and the science behind our lead program, BB-031.
In the recording below, our CEO, Julia Owens, and Co-founder and Chief Scientific Officer, Dr. Shahid Nimjee, walk through the stroke treatment landscape, why targeting von Willebrand Factor represents a fundamentally different approach, and where BB-031 stands in its clinical development.
Thank you, Josh and the Cantor team, for the opportunity to share our story with your audience.
Stay updated with Hemostasis Today.
-
Nov 15, 2026, 16:29Jean-Jacques Kiladjian: 20 Years of Interferon-Alpha Research in Myeloproliferative Neoplasms
-
Nov 15, 2026, 16:21Sukanto Paul: Why Platelet Transfusion Is Generally Avoided in TTP
-
Nov 15, 2026, 16:14Ahmad G. Alzahrani: Major Bleeding and Anticoagulant Reversal
-
Nov 15, 2026, 16:05Sabine Eichinger: Is Recurrence Risk After Provoked VTE Really Low?
-
Nov 15, 2026, 15:53Nicolas Schommer: The Seed and Soil Hypothesis of NET-Mediated Inflammation
-
Nov 15, 2026, 15:36Giovanni Merlino: Targeting LDL-C to Prevent Recurrent Stroke
-
Nov 15, 2026, 15:33Riitta Lassila: From Helsinki to ISTH 2027 Advancing Thrombosis Research
-
Nov 15, 2026, 15:30Andreas Calatzis: Can Protein C and Plasma Overcome Fibrinolysis Resistance in Sepsis?
-
Nov 15, 2026, 15:25Hussnain Javaid: Thalassaemia 2026 New Therapies Transforming UK Practice